Cardiac Mapping Market Report 2024

The cardiac mapping market size has grown strongly in recent years. It will grow from $2.15 billion in 2023 to $2.3 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. During the historic period, growth in cardiac mapping technologies can be attributed to several factors, including the introduction of catheter ablation procedures, advancements in 3D mapping systems, improvements in imaging technologies for better visualization of the heart's electrical activity, an increase in the prevalence of cardiac arrhythmias among the population, and the expansion of minimally invasive procedures for treating heart conditions.

The cardiac mapping market size is expected to see strong growth in the next few years. It will grow to $3.06 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. In the forecast period, growth in cardiac mapping technologies can be attributed to several factors, including the increasing prevalence of cardiovascular diseases globally, a growing aging population leading to higher incidences of heart conditions, rising awareness and implementation of screening programs for early detection, improvements in healthcare infrastructure supporting advanced cardiac care, and an overall increase in health issues requiring accurate cardiac diagnostics and treatments. Major trends expected in this period include the integration of artificial intelligence (AI) to enhance data analysis and interpretation, the adoption of real-time 3D mapping systems for precise visualization of cardiac structures and electrical activity, advancements in catheter technologies for more effective procedures, the utilization of cloud-based platforms for data storage and analysis, and improvements in electrophysiology software to optimize diagnostic accuracy and treatment outcomes.

The cardiac mapping market is poised for growth due to increasing prevalence of heart ailments, which encompass various conditions affecting the heart's structure and function, leading to complications such as arrhythmias, heart attacks, and heart failure. Sedentary lifestyles, poor dietary habits, and aging populations contribute to the rising incidence of these ailments. Cardiac mapping plays a crucial role in diagnosing and treating heart conditions by precisely identifying electrical abnormalities in the heart's rhythm. For example, the British Heart Foundation reported in January 2024 that over one million individuals in the UK suffer from heart failure, with approximately 200,000 new cases diagnosed annually and around 730,000 people included in GP heart failure registers. This underscores how the prevalence of heart ailments is fueling growth in the cardiac mapping market.

Leading companies in the cardiac mapping market are focusing on developing advanced solutions such as cardiac mapping platforms to improve diagnostic precision and treatment effectiveness. These platforms employ sophisticated technologies to visualize and analyze electrical activity within the heart, aiding in the diagnosis and treatment of cardiac arrhythmias and other conditions. For instance, Abbott Laboratories, a US-based healthcare company, received FDA 510(k) clearance in January 2022 for its EnSite X EP system. This platform helps physicians pinpoint origins of abnormal heart rhythms by generating detailed 3D maps that offer a comprehensive 360-degree view, regardless of catheter orientation. The system utilizes Abbott's proprietary EnSite omnipolar technology (OT) and advisor HD grid catheter to capture accurate electrograms from any catheter angle.

In August 2022, Medtronic Plc, a US-based medical technology firm, acquired Affera Inc. for $925 million. This acquisition expands Medtronic's cardiac ablation portfolio to include Affera's advanced cardiac mapping and navigation platform, alongside its diagnostic and therapeutic catheters. Affera Inc., based in the US, specializes in developing systems for cardiac mapping and ablation.

Major companies operating in the cardiac mapping market are Johnson & Johnson, Abbott Laboratories, Medtronic plc, Koninklijke Philips N.V., GE Healthcare Technologies, Boston Scientific Corporation, Epmap-System, APN Health LLC, BIOTRONIK SE & Co. KG, Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Biosense Webster Inc., BioSig Technologies Inc., CardioFocus Inc., Kardium Inc., Acutus Medical Inc., Navix Medical Ltd., EP Solutions SA, CoreMap Inc., Catheter Precision Inc.

North America was the largest region in the cardiac mapping market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac mapping market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cardiac mapping market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cardiac mapping involves creating a detailed representation of the heart's electrical activity to pinpoint abnormal rhythms (arrhythmias) by mapping the location and patterns of electrical impulses. This data is essential for diagnosing and treating various cardiac conditions and guiding procedures such as ablation therapy to correct irregular heartbeats.

The primary types of cardiac mapping systems are contact cardiac mapping and non-contact cardiac mapping. Contact cardiac mapping systems utilize electrodes in direct contact with heart tissue to precisely identify and map electrical activity. They are used for diagnosing and treating conditions such as atrial fibrillation, atrial flutter, and atrioventricular nodal reentrant tachycardia (AVNRT). These systems are employed by hospitals, clinics, diagnostic centers, and other healthcare facilities.

The cardiac mapping research report is one of a series of new reports that provides cardiac mapping market statistics, including the cardiac mapping industry's global market size, regional shares, competitors with a cardiac mapping market share, detailed cardiac mapping market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac mapping industry. This cardiac mapping market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cardiac mapping market consists of revenues earned by entities by providing services such as monitoring and follow-up, diagnostic mapping, and ablation guidance. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiac mapping market also includes sales of electrophysiology mapping systems, mapping software, navigation systems, and ablation catheters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.